Comparison of Localized and Systemic Otitis Media With ANCA-Associated Vasculitis.

OBJECTIVE To investigate differences in immune activity based on the presence of multiple organ involvement in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) and whether hearing outcomes are different between patients with AAV localized to the ear and patients with systemic AAV. STUDY DESIGN Retrospective case review. SETTING University hospital. PATIENTS Twenty patients with otitis media with AAV (OMAAV) who met the criteria proposed by the OMAAV study group in Japan. MAIN OUTCOME MEASURE(S) Serum levels of C-reactive protein, ANCA titer, soluble interleukin-2 receptor levels, and hearing outcome. RESULTS Thirteen patients had disease involvement of organs other than the ear (systemic OMAAV group); involvement was localized to the ear in seven patients (localized OMAAV group). Serum levels of C-reactive protein, ANCA titer, and soluble interleukin-2 receptor were not significantly different between the groups. Hearing levels at diagnosis and in remission were significantly worse in the localized OMAAV group compared with the systemic OMAAV group. Hearing gain was not significantly different between groups. CONCLUSION It is suggested that immune activity in patients with AAV localized to the ear is equivalent to activity in patients with systemic AAV. Therefore, we may need treatment for OMAAV equal in intensity to that for systemic AAV. As the hearing level at diagnosis was worse in patients with AAV localized to the ear than in patients with systemic AAV, earlier diagnosis may be needed to improve hearing outcome.

[1]  Christopher C. Griffith,et al.  Idiopathic, Infectious and Reactive Lesions of the Ear and Temporal Bone , 2018, Head and Neck Pathology.

[2]  K. Kishibe,et al.  Clinical features and treatment outcomes of otitis media with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (OMAAV): A retrospective analysis of 235 patients from a nationwide survey in Japan , 2017, Modern rheumatology.

[3]  N. Yoshida,et al.  Reversible Cochlear Function With ANCA-Associated Vasculitis Initially Diagnosed by Otologic Symptoms , 2014, Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology.

[4]  H. Makino,et al.  Comparison of Phenotype and Outcome in Microscopic Polyangiitis Between Europe and Japan , 2013, The Journal of Rheumatology.

[5]  N. Yoshida,et al.  Pathogenesis and diagnosis of otitis media with ANCA-associated vasculitis. , 2014, Allergology international : official journal of the Japanese Society of Allergology.

[6]  T. Horiuchi,et al.  Characteristics of MPO-ANCA-positive granulomatosis with polyangiitis: a retrospective multi-center study in Japan , 2014, Rheumatology International.

[7]  Y. Tomino,et al.  Severity-based treatment for Japanese patients with MPO-ANCA-associated vasculitis: the JMAAV study , 2011, Modern rheumatology.

[8]  W. Szyfter,et al.  Otologic Symptoms as Initial Manifestation of Wegener Granulomatosis: Diagnostic Dilemma , 2011, Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology.

[9]  F. Moosig,et al.  Prospective long-term follow-up of patients with localised Wegener's granulomatosis: does it occur as persistent disease stage? , 2010, Annals of the rheumatic diseases.

[10]  R. Falk,et al.  Pathogenesis of vascular inflammation by anti-neutrophil cytoplasmic antibodies. , 2006, Journal of the American Society of Nephrology : JASN.

[11]  C. Kallenberg,et al.  Plasma levels of soluble IL-2R, soluble CD30, IL-10 and BAFF during follow-up in PR3-ANCA-associated vasculitis: associations with disease activity and relapse , 2006 .

[12]  C. Kallenberg,et al.  Plasma levels of soluble interleukin 2 receptor, soluble CD30, interleukin 10 and B cell activator of the tumour necrosis factor family during follow-up in vasculitis associated with proteinase 3-antineutrophil cytoplasmic antibodies: associations with disease activity and relapse , 2006, Annals of the rheumatic diseases.

[13]  W. Arnold,et al.  Otological Wegener's granulomatosis at the time of initial presentation: a potential diagnostic dilemma , 2003, Acta oto-laryngologica.

[14]  E. Mirapeix,et al.  Serum levels of soluble interleukin-2 receptor in patients with ANCA-associated vasculitis. , 2000, Journal of nephrology.

[15]  C. Kallenberg,et al.  Serum markers of T cell activation in relapses of Wegener's granulomatosis , 1993, Advances in experimental medicine and biology.

[16]  C. Heesen,et al.  Elevated serum levels of soluble interleukin-2 receptor in patients with Wegener's granulomatosis. Association with disease activity. , 1992, Arthritis and rheumatism.

[17]  L A Rubin,et al.  The soluble interleukin-2 receptor: biology, function, and clinical application. , 1990, Annals of internal medicine.

[18]  T. H. The,et al.  AUTOANTIBODIES AGAINST NEUTROPHILS AND MONOCYTES: TOOL FOR DIAGNOSIS AND MARKER OF DISEASE ACTIVITY IN WEGENER'S GRANULOMATOSIS , 1985, The Lancet.